Poxel S.A., a clinical-stage biopharmaceutical company headquartered in Lyon, France, has been making significant strides in the biotechnology sector, particularly in the development of novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. Incorporated in 2009, Poxel has established itself as a key player in the health care industry, focusing on innovative therapeutic solutions targeting mitochondrial dysfunction.
One of Poxel’s flagship products, TWYMEEG (Imeglimin), has garnered attention for its approval in Japan as a treatment for type 2 diabetes. This oral drug candidate is designed to address mitochondrial dysfunction, a common underlying factor in metabolic diseases. The success of Imeglimin in Japan marks a significant milestone for Poxel, highlighting its potential in the global market. The development and commercialization of Imeglimin are further supported by a strategic partnership with Sumitomo Pharma, which underscores the collaborative efforts driving Poxel’s advancements.
In addition to Imeglimin, Poxel is actively developing PXL770, an adenosine monophosphate-activated protein kinase enzyme. Currently in a Phase 2a clinical trial, PXL770 aims to treat chronic metabolic diseases, including non-alcoholic steatohepatitis (NASH), a progressive liver disease. This development is part of Poxel’s broader strategy to address complex metabolic conditions through targeted therapeutic interventions.
Poxel’s commitment to innovation is further exemplified by its earlier-stage program, PXL065, which is in Phase 2 for the treatment of NASH. This program focuses on chronic and rare metabolic indications, demonstrating Poxel’s dedication to addressing unmet medical needs. The development of PXL065 is supported by a licensing agreement with DeuteRx LLC, emphasizing the collaborative nature of Poxel’s research and development efforts.
Moreover, Poxel has entered into a licensing agreement with Enyo Pharma S.A.S. for the development of a farnesoid X receptor, currently in a Phase 2a study for the treatment of hepatitis B and NASH. This partnership highlights Poxel’s strategic approach to leveraging external expertise and resources to advance its therapeutic pipeline.
As of November 18, 2025, Poxel’s close price stood at 0.2485 EUR, with a market capitalization of 13,798,519 EUR. The company’s stock has experienced fluctuations over the past year, reaching a 52-week high of 0.83 EUR on June 1, 2025, and a low of 0.115 EUR on December 9, 2024. These financial metrics reflect the dynamic nature of the biotechnology sector and the potential growth opportunities for Poxel as it continues to develop and commercialize its innovative treatments.
In summary, Poxel S.A. is at the forefront of developing novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. Through strategic partnerships and a focus on mitochondrial dysfunction, Poxel is poised to make significant contributions to the health care industry. As the company progresses with its clinical trials and commercialization efforts, it remains a promising entity in the biotechnology sector, with the potential to improve the lives of patients worldwide.
